‘It’s not an easy pill to take’: The first highly anticipated GLP-1 pill is here, but physicians aren’t sure it has the ...

Novo Nordisk CEO Maziar Mike Doustdar acknowledged the market pressure facing the company’s GLP-1 products but sought to ...

Major equities indexes ended higher Monday after sharp gains to end last week, as tech stocks lifted the S&P 500 and Nasdaq, ...

Operation Louisiana Shield resulted in 742 arrests and the seizure of drugs tied to Mexican cartels, including 176 firearms ...

The split in outlook underscores Lilly's strong position in the obesity market, underpinned by more effective drugs and its ...

NEW YORK, Feb 6 (Reuters) - Hims & Hers sent a shockwave through the pharmaceutical industry on Thursday with its ...

Wegovy, a weight-loss drug that helps people slim down, is bulking up for its first appearance in the Super Bowl. Novo ...

Consumer Reports testing shows how certain wireless speakers underperform, even when they cost more or promise extra features ...

The S&P 500 rose on Monday, boosted by technology stocks, while the Dow Jones Industrial Average reached new heights as ...

Downgrade Hims & Hers Health, Inc. to Hold as FDA scrutiny and Novo’s lawsuit threaten compounded GLP-1 revenue. Click for ...

By Mrinalika Roy and Mariam Sunny Feb 4 (Reuters) - Eli Lilly forecast strong profit growth for 2026 on Wednesday on the back ...

Telehealth giant Hims & Hers Health, Inc. HIMS may have flown too close to the sun and is now under fire on multiple fronts, including federal intervention, criminal investigation and a patent war.